Background In Saudi Arabia, sickle cell disease (SCD) is a major public health issue,
especially in the eastern region. Sickle cell patients have major health-related issues …

Background and Objectives: Hydroxyurea (HU) is an effective medication used to reduce the
frequency of painful crises associated with sickle cell disease (SCD). However, data …

Background: Sickle cell disease (SCD) is a disorder marked by a single-point mutation in the
beta-globin gene. Hydroxyurea is a globally accepted disease-modifying agent that sounds …

Background: Sickle cell disease (SCD) is a prevalent genetic disorder characterized by
abnormal hemoglobin formation, resulting in severe complications. Hydroxyurea (HU) …

Hydroxyurea (HU) is used as a disease-modifying agent in sickle cell disease (SCD). Its
beneficial effects have been ascribed to inhibition of the sickling process through increase of …

ABSTRACT Introduction: Sickle Cell Disease (SCD) is an autosomal recessive multisystem
disorder, characterised by anaemia, recurrent episodes of pain and chronic organ damage …

Background: The clinical prospects of hydroxyurea therapy in the management of sickle cell
disease (SCD) require evaluation in the Nigerian setting to develop indigenous guidelines …

Sickle cell disease (SCD) is a group of inherited disorders of hemoglobin synthesis. It is
prevalent in different parts of the world, including the Kingdom of Saudi Arabia. The disease …

Background: Hydroxyurea is underutilized by sickle cell health-care providers in Nigeria
despite available evidence of its effectiveness in reducing the manifestations and …

Background: We tried to understand possible effects of hydroxyurea therapy on health
parameters in sickle cell diseases (SCDs). Methods: All patients with SCDs were enrolled …